Plain-English translation of NCT06446050 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new immunotherapy called (mesenchymal stem cells modified to mobilize lymphocytes) for people with advanced colorectal cancer. The treatment uses stem cells from umbilical cord blood that have been engineered in the laboratory to express special molecules that attract and activate immune cells. Once these modified cells are infused into your bloodstream, they travel to your tumor and work to recruit and activate your body's own T cells and natural killer cells to attack the cancer.
Many people with advanced colorectal cancer do not respond well to standard immunotherapy treatments, and their tumors create an environment that suppresses the immune system. This trial exists to test whether this medication can overcome that suppression by bringing immune-boosting signals directly into the tumor.
You likely qualify if…
You likely don't qualify if…
You would receive infusions of the modified stem cells through your vein every 21 days (roughly every three weeks). The trial will start by testing different doses with the first group of patients to find the safest and most effective dose; once that is determined, remaining patients will receive that optimal dose. You would be monitored closely with regular blood tests and imaging to assess how well the treatment is working and to watch for any side effects.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
China